Key cardiology trial outcomes and mRNA cancer vaccine hopes emerge from ESC Congress

During the European Society of Cardiology Congress in Munich, several cardiovascular developments were unveiled. Novartis reported that its newly acquired antibody, pacibekitug, lowered inflammation markers in a mid-stage trial by targeting the interleukin-6 pathway, though some experts remain cautious. AstraZeneca announced a surprise setback for its experimental silencer drug, which failed to provide extra benefit to patients with ATTR-CM already receiving stabilizer therapy.

Cytokinetics presented full pivotal data for aficamten, showing that patients with non-obstructive hypertrophic cardiomyopathy experienced symptom relief and increased exercise capacity, positioning the drug for possible first-in-class approval. In parallel, Moderna and Merck disclosed top-line results of an mRNA neoantigen vaccine that cut the chance of melanoma recurrence after surgery, a finding that could soften vaccine stigma.

The conference also featured a projection from the European Association for the Study of Diabetes forecasting a 29% increase in worldwide type-1 diabetes cases by 2049, and commentary on how pet ownership influences medical decisions and on accelerating radiopharmaceutical dosing regimens. These updates collectively signal potential shifts in heart disease treatment, cancer immunotherapy, and chronic disease burden.